This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.

Biomarkers for duodenal cancers

  • Research type

    Research Study

  • Full title

    Identify a predictive or prognostic biomarker for duodenal adenocarcinoma

  • IRAS ID

    153078

  • Contact name

    Hemant Kocher

  • Contact email

    h.kocher@qmul.ac.uk

  • Sponsor organisation

    Queen Mary University of London

  • Duration of Study in the UK

    5 years, 0 months, 1 days

  • Research summary

    The aim of this study is to identify novel biomarkers which could be applied to duodenal cancer samples, in order to improve treatment and outcomes for these patients. In recent literature it is documented the outcomes for duodenal cancer are generally poor. This is largely due to late presentation or difficult surgery due to location of tumour deep inside the abdomen. [Solani et al, British Journal of Surgery 2015].

    At the moment there are no specific biomarkers for duodenal cancer that could be used for diagnosis or to predict response to treatment.

    Duodenal adenocarcinoma tissue samples would be retrieved from a previous UK Duodenal Cancer Study Group (UKDCSG) cohort of patients. This was a collaborative study, to investigate a cohort of duodenal adenocarcinoma patients from six sites across the United Kingdom. UKDCSG is therefore the largest cohort of duodenal cancer patients analysed to date anywhere in the world. Another site has joined the UKDCSG for this research project to increase the cohort further.

    These samples will be retrieved from their current storage sites (usually the pathology departments). A single paraffin block from the surplus tissue which was removed at surgery will be transferred to Barts Cancer Institute. The choice of block will be determined by content of maximal tumour and some adjacent normal duodenal tissue. These Samples would be anonymised. The in-house pathology department will then cut these samples into thin sections and mounted onto slides. The slides will then be stained using as standard protocols for Haematoxylin & Eosin and assessed for type of tissue and its content for quality control.

    These samples will then further undergo a series of research tests for biomarker development. These include staining with known biomarkers for analysis and interpretation, to either validate or refute previous hypotheses. Examples include Ki67, MUC1, Beclin1 staining.

  • REC name

    North East - Tyne & Wear South Research Ethics Committee

  • REC reference

    16/NE/0130

  • Date of REC Opinion

    6 Apr 2016

  • REC opinion

    Favourable Opinion